Study Group: Physicians who Treat Oral Mucositis(?)
Council Members in this Study Group: 28
Request a survey with this Study Group
Leading Experts in this Study Group
Assistant Professor of Medicine
University of Pennsylvania Cancer Center
Donald Tsai, MD, PhD, is Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....
Haitham Al-Okk, MDAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center
Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other...
The company claims that Erbitux has shown survival benefit in lung cancer (NSCLC) in the current Phase III trial. how much benefit? what are its implications?
no doubt that Velcade has shown superior results . it deserved to be used as induciton regimen ( unles patient has pre-existing neuropathy) for transplant. velcade is more efficacious ,less toxic and more easier to give than VAD regimen.
Spyglass technology may represent a huge new market for Boston Scientific and is their first foray in the the world of endoscopes (rather than endoscopic devices). While cholangioscopy has been around years, Spyglass offers unique advantages over standard cholangioscopes. There are...
The current treatment for patients with hepatitis C genotype 1 is not optimal. The standard therapy with Peg interferon and ribavirin has an efficacy rate of 48%. The preliminary efficacy data of the combination therapy by adding telaprivir to peg interferone and ribavirin is outstanding at 88%. Only...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Government/Military Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Consultancy, Healthcare-Focused
- Pharmaceuticals Manufacturer
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Consultant
- Owner
- Research Scientist
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms